Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dracorhodin perchlorate is a synthetic derivative of dracorhodin, a natural pigment compound found in the traditional Chinese medicine dragon’s blood (primarily from Daemonorops draco or Dracaena draconis). It is used in preclinical research and is known for its pro-apoptotic and anti-proliferative effects, including induction of cell cycle arrest and apoptosis in various cancer cell lines. Dracorhodin perchlorate also exhibits wound-healing properties by promoting fibroblast proliferation and enhancing growth factor expression (notably bFGF and EGF). Additionally, it inhibits high glucose-induced serum and glucocorticoid-induced protein kinase 1 (SGK1) and fibronectin (FN) expression in human mesangial cells, which may contribute to antifibrotic and potential antidiabetic nephropathy actions. It is not approved for clinical or therapeutic use and is available only for research purposes[1][2][3][5][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dracorhodin perchlorate.